Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of inherited kidney disease worldwide. Over the past five years, the therapeutic pipeline for ADPKD has expanded, leading to a growing need for patient enrollment in clinical trials and improved understanding of patient-centered outcomes that can be used in trial design. To advance these goals, the Polycystic Kidney Disease Foundation (PKDF) established a national web-based ADPKD Registry., Methods: The ADPKD Registry is hosted on a secure, HIPAA-compliant, online platform (IQVIA, oc-meridian.com/pkdcure). Participants are consented through the online system and complete a series of modules. The Core Questionnaire includes patient-reported diagnosis, latest creatinine values, and comorbidities. Additional modules include surveys of family history, diet, quality of life, extrarenal manifestations, and attitudes surrounding research participation., Results: As of October 2021, 1563 ADPKD patients across the United States have registered and completed the Core Questionnaire. Participants have a median age of 44 years and are 72% women, 93% White, with 4% self-identifying as Hispanic/Latino and 2% as Black. All CKD stages are present, including post kidney transplant. To date, seven clinical studies have used the Registry as a recruitment tool. Additionally, quality-of-life burden scores revealed a correlation with disease stage as determined by kidney function., Conclusions: The Registry described here is the only one of its kind and is a valuable longitudinal research tool encompassing all stages of ADPKD. The registry will allow investigators to pursue a range of research questions related to the management of ADPKD, including definition of health-related quality of life (HRQoL) outcomes and recruitment for a variety of observational and therapeutic clinical protocols., Competing Interests: B. Benson reports being a member of the Polycystic Kidney Disease Foundation (PKDF) Board of Directors (unpaid position) and the Northeastern University Biotechnology Center of Excellence Scientific Advisory Board. N.K. Dahl reports consultancy for Otsuka Pharmaceuticals and Vertex; research funding as a PI for clinical trials sponsored by Allena, Kadmon, Reata, Regulus, and Sanofi; honoraria from AstraZeneca, the National Kidney Foundation, and Otsuka Pharmaceutical; an advisory or leadership role for the Natera Scientific Advisory Board and the PKDF; participation in a speakers’ bureau for Otsuka; and other interests or relationships with the Medical Advisory Board, NKF NE Chapter. B. Gitomer reports honoraria from the Department of Defense UD study section and the National Institute of Diabetes and Digestive and Kidney Diseases for study section participation; and an advisory or leadership role for CJASN (editorial board member) and the PKDF (member of the Scientific Advisory Council). E. Hoover reports being an employee of the PKDF. M. Mrug reports consultancy for Caraway Therapeutics, Chinook, Goldilocks Therapeutics, Natera, Otsuka Corp., Reata, and Sanofi; research funding from Chinook, Goldilocks Therapeutics, Otsuka Corp., Palladio, and Sanofi; honoraria from Chinook, Natera, Otsuka Corp., Reata, and Sanofi; and an advisory or leadership role for Carraway Therapeutics (advisory board), Goldilocks Therapeutics (advisory board), the PKDF, Sanofi (STAGED-PKD steering committee), and Santa Barbara Nutrients (advisory board). M. Park reports consultancy for Abalone Bio and Acelink Therapeutics; ownership interest in Merck (spouse); honoraria from Grand Rounds and Healthcare Consultancy Group; and other interests or relationships with Kadmon (site PI for tesevatinib trial), Reata (site PI for bardoxolone FALCON trial), Sanofi (site PI for venglustat SAVEPKD trial [now terminated]), and being an advisory board participant for Otsuka, Reata, and Sanofi. R.D. Perrone reports consultancy for Caraway, Navitor, Otsuka, Palladiobio, Reata, Sanofi-Genzyme; research funding from Kadmon, Palladiobio, Reata, and Sanofi; honoraria from Otsuka, Reata, and Sanofi-Genzyme; an advisory or leadership role for Otsuka, PalladioBio, and Sanofi-Genzyme; participation in a speakers’ bureau for Haymarket Media; and other interests or relationships with the Critical Path Institute, the PKDF, and UpToDate. C. Rusconi reports being an employee of the PKDF. S.L. Seliger reports consultancy for Tricida, Inc. (Endpoint Adjudication Committee); research funding from Kadmon Pharmaceuticals, Palladio Biosciences, Reata, Roche Diagnostics, Inc., and Sanofi US; patents or royalties from the University of Maryland, Baltimore, and University of Texas, Southwestern (Methods for Assessing Differential Risk for Developing Heart Failure); and an advisory or leadership role for Circulation (member of the editorial board), CJASN (associate editor), Endpoint Adjudication Committee (member), ESRD Network 5 (member), the Medical Review Board (member), and Tricida, Inc. (VALOR-CKD trial). T.J. Watnick reports research funding for clinical trials sponsored by Palladio Biosciences and from Reata (study site for the Falcon Study); patents or royalties from AThena Diagnostics (PKD DNA testing) and UpToDate (royalties declined); an advisory or leadership role for JASN (editorial board) and the PKDF Registry (Scientific Advisory Committee); and serving on advisory committees for the PKDF. All remaining authors have nothing to disclose., (Copyright © 2022 by the American Society of Nephrology.)